HSP90AA1 and prostate cancer: Based on the aforementioned limitations using rabbit reticulocyte lysates, a cell-based luciferase assay was optimized using both N-terminal and C-terminal Hsp90 inhibitors in prostate cancer cell lines (Figure 6A-D).